局限性前列腺癌单日两次大分割HDR近距离放疗的长期结局
这项前瞻性队列研究纳入120例低危或中危局限性前列腺癌患者,单日接受2次HDR近距离放疗。中位随访123个月,全组无生化证据疾病生存率93.3%,总生存率86.7%,局部控制率95.2%,无转移生存率96.1%。PSA最低值≤0.20 ng/mL者10年无生化证据疾病生存率为96.9%,未达此水平者仅为40%。
要点
- 单日2次HDR近距离放疗后中位随访123个月,全组无生化证据疾病生存率93.3%。
- PSA最低值≤0.20 ng/mL者10年无生化证据疾病生存率96.9%,未达此水平者为40%。
- 作者结论认为,在预后良好的局限性前列腺癌中,该方案是高度治愈性的放疗技术。
核心结论
- 在预后良好的局限性前列腺癌患者中,单日2次HDR近距离放疗单药治疗是高度治愈性的放疗技术,95%的病例可达到PSA最低值<0.2 ng/mL。
研究设计与样本
- 前瞻性队列研究,纳入120例低危或中危局限性前列腺癌患者,依据NCCN实践指南分组,其中低危84例、中危36例。
- 患者于2010年11月至2016年2月期间接受单日2次HDR近距离放疗单药治疗。
主要发现
- 中位年龄66岁(范围45-84岁),中位PSA为7.5 ng/ml(范围0.01-16 ng/ml)。
- 84.2%的患者Gleason评分为6分,15.8%为7分;31%的患者接受了ADT。
- 中位随访123个月,全组无生化证据疾病生存率、总生存率、局部控制率和无转移生存率分别为93.3%、86.7%、95.2%和96.1%。
- 达到PSA最低值的中位时间为80.5个月。
- PSA最低值≤0.20 ng/mL的患者10年无生化证据疾病生存率为96.9%,未达到该PSA水平的患者为40%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: We previously published the toxicity and initial results of a prospective cohort of patients treated with 2 fractions HDR-BRT administered in a single day. In the present analysis we report the long-term cancer control results of our prospective trial and investigate the relationship between PSA nadir and biochemical control. MATERIAL AND METHODS: A total of 120 patients were treated with HDR Brachytherapy monotherapy administered in two fractions in a single day. Between November 2010 and February 2016, 84 patients with low-risk and 36 patients with intermediate-risk prostate cancer in accordance with the NCCN practice guidelines. RESULTS: Median age was 66 years (range 45-84) and median PSA was 7.5 ng/ml (range 0.01-16 ng/ml). Overall, 84.2% had Gleason score 6 and 15.8% Gleason 7. Thirty-one percent of patients received ADT.After a median follow-up of the cohort was 123 months. Actuarial rates of no biochemical evidence of disease (bNED), overall survival, local control and metastasis-free survival for all patients were 93.3%, 86.7%, 95.2% and 96.1%, respectively.The median time to achieve PSA nadir was 80.5 months. Patients who attained a PSA Nadir ≤ 0.20 ng/mL exhibited a 10-year bNED survival rate of 96.9%, whereas thosewho failed to reach this PSA level had a survival rate of only 40%. CONCLUSIONS: In patients with favorable localized prostate cancer, 2 fractions HDR-BT monotherapy is a highly curative radiation technique that attains PSA nadir levels < 0.2 ng/mL in 95% of cases.
引用
- Nagore G, Moreno-Olmedo E, Suárez-Gironzini V, et al. Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer. Radiother Oncol. 2023. PMID: 37437606. doi:10.1016/j.radonc.2023.109807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。